Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
New pressures notwithstanding, being a cancer center director is still a dream job, two of the nation’s newest cancer center directors said.
Ready or not, AI-based decision support tools are entering oncology clinics
Regulators and health systems must adapt
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA has granted an accelerated approval to RP1 (vusolimogene oderparepvec) following the agency’s Cellular, Tissue, and Gene Therapies Advisory Committee’s 10:3 vote in support of the biologic in combination with nivolumab for the treatment of advanced melanoma in patients who have progressed on prior anti-PD-1 therapy.
When it comes to harnessing artificial intelligence for cancer breakthroughs, Johns Hopkins researchers Alex Szalay, PhD, and Janis Taube, MD, MSc, believe the future begins with data—lots of it.
FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.
In last week’s issue of The Cancer Letter, the cover story featured coverage of Kalshi, an online prediction market exchange, launching a pilot program in which one can place bets on both outcomes of trials and FDA decisions.
FDA’s Oncology Center of Excellence has published three final guidance documents intended to broaden eligibility criteria for participation in clinical trials of oncology drugs.
